Therna Biosciences, a biotechnology company pioneering programmable RNA therapeutics, has joined forces with Charles River to advance single-patient RNA medicines for individuals with severe, ultra-rare disorders. The first two programs under the collaboration focus on an adult patient with a rapidly progressive, rare form of lung fibrosis and a newborn with an ultra-rare central nervous system disorder called Lamb-Shaffer Syndrome. The collaboration brings together Therna’s expertis...